untitled
|
|
- えの かたいわ
- 5 years ago
- Views:
Transcription
1
2 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2)
3 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3
4 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) ( ) mg( ) 360mg 6. 10mg 20mg /m mg 4
5 mg 15mg 30mg 15mg 30mg 5 20mL 1 5mg 15mg 30mg 5mL 1mg /1mL 5mg 15mg mg 5
6 Streptomyces verticillus PVB Ann Intern Med 87: , 1977 D VAB-6 Ann Intern Med 95: 59-61, 1981 BEP Br J Cancer 47: , 1983 BEP Int. J. Cancer 53: ,
7 SuSa GH 833K 1618K GCT27 IC ng/ml 2.4 ng/ml IC ng/ml 0.15 ng/ml ng/ml 29.0 ng/ml ng/ml 21.5 ng/ml Investigational New Drugs 8: S19-S24, 1990 line H 12.1 line H line H mg/kg mg/kg mg/kg mg/kg 600mg/kg mg/kg mg/kg mg/kg mg/kg line H , : 1983 JTG-1 4mg/kg 5 0.5mg/kg 2 0.1mg/kg % 4mg/kg % 44(4), , 1990 YST-1 YST-2 YST-3 T/C YST-1 YST-2 YST-3 90mg/kg 4 3 T/C % 30mg/kg 0.6mg/kg 2mg/kg 4 3 T/C % DNA J. Med. 7, , 1976 DNA XRCC X-ray repair cross-complementing 1 XRCC Cancer Res. 58, , 1998 DNA DNA 7
8 XRCC1 XRCC1 Carcinogenesis 23, , J. Antibiot. 25, , (1) -1 Cancer 31: , mg/kg 2 400mg VBL VBL mg / /20 VBL % 22% 17% 14% 13% 10% 10% 8% (2) BEP PVB -2 N Engl J Med 316: ,
9 Indiana 261 PVB CDDP VBL BEP ETP CDDP CR PVB 61 74/121 BEP 60 74/123 PVB 12 BEP 23 PVB 74 BEP 83 M.D.Anderson Indiana Advanced BEP PVB M.D.Anderson :p 0.05 Indiana p= % BEP PVB M.D.Anderson :p=0.048 Indiana p=0.017 log-rank 59% 500/mm 3 BEP PVB p ,000/mm 3 PVB 5 BEP 14 PVB 2 BEP 6 PVB 38%:23, p 0.02 PVB 20%:5, p= PVB 19 BEP 1 p= PVB 4 BEP 2 PVB 2 BEP 3 PVB 1 BEP PVB (3) PVB PV -3 J Clin Oncol 11: , PVB PV PV 108 PVB 110 CR PV 82 PVB 87 PV 89 PVB 94 p= PV 7 PVB 5 PV PVB (p=0.70 log-rank ) PV PVB 6 5 PV p=0.02 9
10 PVB PV PVB CDDP PV (4) BEP 4 EP 4-4 J Clin Oncol 15: , 1997 EORTC(European Organization for Research and Treatment of Cancer) 419 BEP 4 EP BEP 200 EP 195 CR BEP 92 EP 85% (p=0.0276) BEP 95% EP 87% (p=0.0075) 7.3 4% 10 BEP : EP : p log-rank ; BEP EP HR : CR p 0.83, HR 1.1; 95 ; p 0.262, HR 1.67; 95 ; , CR p 0.702, HR 1.24; 95 ; BEP :3, EP :1 BEP EP 1 7 BEP BEP (p<0.001) BEP 2 BEP (5) BEP 3 BEP 4-5 J Clin Oncol16: , 1998 Indiana BEP BEP 3 56 BEP p 0.80, p=0.93 log-rank Cox HCG HCG 1,000 miu/ml HCG>1,000 10
11 miu/ml 14 5 p<0.001 BEP 3 4 (6) BEP 3 EP 3-6 J Clin Oncol 13: , 1995 ECOG(the Eastern Cooperative Oncology Group) 178 BEP 3 EP BEP 86 EP 85 CR BEP 77 EP 71 BEP 94 EP 88 p=0.20 BEP 3 3/86 EP 11 9/85 BEP 2 2/86 EP 9 8/85 EP BEP 10 8/81 EP 23 17/75 EP EP 38 32/85 BEP 17 15/86 p BEP 95 EP 86 BEP p=0.01 log-rank 3 BEP (7) BEP 4 VIP 4-7 J Clin Oncol 16: , 1998 ECOG SWOG(the Southwestern Oncology Group) CALGB(the Cancer and Leukemia Study Group B) 304 BEP VIP (ETP CDDP) CR BEP 31 43/141 VIP 37 54/145 p=0.26 FR (favorable response) CR 2 PR BEP 60 83/139 VIP 63 89/142 2 BEP 71 VIP 74 p=0.78 log-rank 2 failure-free BEP 60 VIP 64 p=0.29 log-rank 299 Grade 3 VIP BEP p<0.001 VIP BEP 11
12 p= BEP (8) PVB VAB-6 BVP PEB -8 82(6); , PVB CDDP VBL VAB-6 -D ACT-D VBL CDDP) ETP (A ) ETP PEB BEP (B ) A CR PR A 20 B 14 CR A 35% B 43% PR A 45% B 50% 3 A 74 B 100 B A PVB VAB-6 BVP PEB (9) PVeBV -9 87(1): 35-41, 1996 retrospective 8 PVeBV CDDP ETP VBL PVeBV 3 PVeBV 4 CR 46 PVeBV CR PVeBV CR PVeBV (10) -10 Med Pediatr Oncol 23(5): , 1994 GPO(German Society of Pediatric Oncology) PVB PVB PVB PVB VIP A 1 12
13 3 1 PVB (11) BEP -11 J Clin Oncol 12(4): , 1994 GOG Gynecologic Oncology Group BEP (12) ACT-D CDDP 3 BAP -12 Oncology Reports 7: , BEP ETP ACT-D BAP BEP BAP 6 BEP BAP BEP 83.3 p= log-rank 3 BEP BAP BAP (13) -13 Cancer 71(8): , 1993 SWOG BEP ADR EBAP PVB PVB-EBAP / / /41 Nadir 800/ L : / L
14 PVB-EBAP (14) -14 Int J Clin Oncol1: 51-56, PVB PVcBA CDDP VCR ACT-D PVB VAB-6 High-dose BEP 9 6 CR 1 CR 2 PR CR Grade3 high-dose BEP VAB PVcBA PVB 1 VAB-6 BEP 1 2. BEP (Cancer-Principles&Practice of Oncology 6 th ed, Holland-Frei Cancer Medicine ) EP BEP (National Cancer Institute) PDQ Treatment Health Professionals BEP 2(2) 14
15 B III III BEP PVB VAB-6 +VBL+ACT-D+CDDP+CPM PDQ II III BEP 3 CAMPBELL S UROLOGY AJCC III IIA IIB BEP 2-3 C BEP 3 IFM Cancer-Principles&Practice of Oncology AJCC C BEP 3 EP 4 BEP 4 C Holland-Frei Cancer Medicine 5 10cm 10cm CDDP B1,B2 B2 BEP 2 B3 BEP 4 EP
16 BEP 90% BEP yolk sac tumor CR 90 CR PVB BEP (PVB, BEP ) 16
17 VAB-6 20mg/m 2 3 / Z.Kinderchir,44(4): , Br.J.Cancer,62: , 1990 Med.Pediatr.Oncol23(5): , 1994 Pediatr.Hematol.Oncol., 15(3), , 1998 Pediatr. Hematol.Oncol., 17(1), , mg/m Cancer-Principles&Practice of Oncology -3 6 PVB BEP PVB BEP NCI-PDQ BEP BEP 17
18 ABVD ABVD 10mg/m 2 day1 day15 28 ABVD NCI-PCQ: http: // cancernet. nci. nih. gov) 2 15: ,2001 J Clin Oncol16: , 1998 N Eng J Med327: ,1992 BEP PVB 10 20mg/m BEP 15 20mg/m 2 10mg/m mg :/body mg/m mg/m mg/m mg/m VAB-6 modified PVB BEP Proceedings of the American Society of Clinical Oncology, 16, A1840, 511a,1997 Proceedings of the American Society of Clinical Oncology, 17, A2016, 525a, 1998 Proceedings of the American Society of Clinical Oncology, 17, A2017, 525a, 1998 BEP
19 30mg U /body mg 30mg U /body BEP PVB J.Clin.Oncol., 1, ,
20 GCP
21 BEP BEP
22 300mg/body BEP mg(U)/body mg/body 300mg/body mg mg( mg mg / mg / mg /69 451mg / mg 301mg mg mg mg mg BEP 360mg mg / mg / mg / mg mg 360mg 3 pp , 2003 ( ). 29 6, , 2002 BEP BEP NCI PDQ Bosl GJ. et al.:cancer of the testis. In: DeVita VT Jr., Hellman S, Rosenberg SA(Hrsg) : Cancer-Principles & Practice of Oncology 6 th Ed, pp , Lippincott Williams&Wilkins, Philadelphia, 2001 BEP 360mg mg mg mg 300mg 330mg 22
23 BEP BEP 360mg BEP 4 300mg. BEP 300mg BEP J Clin Oncol 7:387-91, 1989 BEP 4 Cancer-Principles & Practice Onclogy 2 7 Br J Cancer 71: , 1995 Cancer 97: , 2003, Jpn J Cancer Chemother 29: , BEP 4 89 Cancer 97: , U 360mg Cancer 97: , 2003 BEP 57% 49% 300mg 360mg 300mg 360mg 150mg( ) mg( ) mg( ) mg/m
24 1.5 m mg/body 1 (30mg) ( ) ( ) 24
25 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) ( ) mg( ) 360mg 6. 10mg 20mg /m mg 25
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More information- 9 91, (2006)
Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM
More informationE3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
More informationuntitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
More informationCRPNo30表紙.ai
No.30 2012/6 20126 Clinical Research Professionals No.30 17 18 Clinical Research Professionals No.30 2012 6 20126 Clinical Research Professionals No.30 19 20 Clinical Research Professionals No.30 2012
More information12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More information化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
More informationuntitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More informationI
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
More informationcm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
More information*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More information1. (1) 1/
2005 11 30 2006 03 31 1-1-2 [ ] 7-12 SMBC 4 1 27 1 18 1. (1) 1/5 1 2 32 1/5 1 2006 3 11 200 2006 1 1/5 20 20 30 CM 10 TVCM15 BB 2006 3 31 26 3 5 2 1 4 3 2 3 (2) (1) 2. (1) 1 2006/03/31 1,680,877,606 1
More information02
54 163116831 02 1 168 54 158 53 162 53 148 52 152 52 10,000 0 40,000 30,000 20,000 50,000 70,000 60,000 1,000 500 1,500 2,000 0 2,500 3,000 4,000 3,500 4,500 168 54 158 53 162 53 148 52 152 52 03 52148
More information<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
More information卵巣癌の治療
K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk
More information薬物治療学分野症例シリーズ7
( 4 ) 1-2 1-2 (New Engl J Med, 2004) I, II III () IV NCI-CTC CTC Version 2.0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ( ( 21 22 23 CTC Version 2.0 24 瘙 Non-steroidal anti-inflammatory
More informationGB 3rd edition final.ppt
Complementary and Alternative Medicine (National Center for Complementary and Alternative Medicine; NCCAM) Complementary and alternative medicine is a group of diverse medical and health care systems,
More information日本皮膚科学会雑誌第120巻第5号
1 2 3 4 5 6 A B 1 2 α β 3 表 1 ClinicalQuestion CQ1 男性型脱毛症にミノキシジルの外用は有用か? (CQ1.1) 男性の男性型脱毛症 (CQ1.2) 女性の男性型脱毛症 CQ2 男性型脱毛症に塩化カルプロニウムの外用は有用か? CQ3 男性型脱毛症に医薬部外品 化粧品の育毛剤の外用は有用か? CQ3.1t- フラバノン CQ3.2 アデノシン CQ3.3
More information33312004_先端融合開発専攻_観音0314PDF用
Advanced Course for Interdisciplinary Technology Development National Institute of Technology, Gifu College Advanced Course for Interdisciplinary Technology Development 1 5 Curriculum National Institute
More informationI? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
More information20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
More information- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
More information2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
More information1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
More information「産業上利用することができる発明」の審査の運用指針(案)
1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)
More information1 1 (1) 1 1 1 (2) 1 (3) 3 3 4 4 2 6 (1) 6 (2) 6 6 6 7 3 7 (1) 7 7 9 10 10 11 (2) 12 12 14 16 (3) 17 17 18 (4) 18 18 18
1 1 (1) 1 1 1 (2) 1 (3) 3 3 4 4 2 6 (1) 6 (2) 6 6 6 7 3 7 (1) 7 7 9 10 10 11 (2) 12 12 14 16 (3) 17 17 18 (4) 18 18 18 ( ) 20 10 26 39 1 2 ( ) 3 338 4 5 6 22 10 7 50 60 8 600 400 600 400 9 10 454 11 45
More informationDNA
1 1 1. 1 2. 2 3. 2 4. 2 2 1. 2 4 5 7 2. 7 3. DNA 8 4. 10 13 Plasmodium (P. falciparum) (P. vivax) (P. malariae) P. ovale 4 40% 200 7 40 48 72 1. - 1 - 2. DNA 3 3. 1) 2) 3) 4) 4. 1 1) - 2 - 2) EDTA 1) 1
More information新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More informationuntitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
More information,328 C 6426 H 9900 N 1700 O 2008 S , ,
2458 13 4 24 1 11 9 17 1,328 C 6426 H 9900 N 1700 O 2008 S 44 145,000 148,000 10 11 27 2 13 4 24 11 9 17 (1) CD20 B CD20 (2) infusion reaction infusion-associated symptom CD20 B 1 375mg/m 2 1 4 3 Heavy
More information0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
More information10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
More information() 2
1 () 2 2 4 3 6,500 4 5 2 6 A B A B A B A B - A B 7 8 A B A B A B 9 JR JR 10 11 6 5 12 17 6 13 14 B A A B A B A B 2 1 8 15 8 16 17 9 18 3 4 5 mm mm 19 2 20 3 6 7 11 12 13 14 18 4 3 2 1 21 3 12 13 14 16
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More information分子標的薬アプデート 2018
Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003
More information日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
More informationuntitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
More informationuntitled
2003 300 2015 500 2015 2006 quality of lifeqol 2012 2016 5 research guideline training practice 4 QOL QOL 2013 3 7 1 8 2 8 1 22 23 2 3 3 47 1 2 3 4. 49 1 50 2 51 1 2 3 4 3 73 1 2 3 4 5 87 1 88 2 88 1 2
More information02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3) 16 3 17 182
6-3. 1. 01. [ 2000 (2003/3),p.161] 02. 1 2 3 1 2 [ 2000 (2003/3),p.160] 03. 12 1 13 15 3 [ 2000 (2003/3),p.207] 04. C C 27 C (1) (2) 3 00 3 C 181 02 12 3 C C C [ (2004/2/28 )] 2. 01. [ (2002/6),p.18] (2004/3)
More information2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More information7) G. N., A. A. Sondore et al.: The Use of Hyperbaric Oxygenation in Intensive Therapy of Patients with Liver Damage. VI Int. Cong. HBO Medicine, Moscow, Sept 2 `6:341, 1981 8) J. J. Moder, M. D.: Phagocytic
More information日本皮膚科学会雑誌第121巻第11号
β Clin Rheumatol Arthritis Rheum Am J Cardiol J Rheumatol J Rheumatol Arthritis Rheum Arthritis Rheum Arthritis Rheum Rheumatology Oxford Rheumatology Oxford Br J Dermatol Arch Dermatol Ann Rheum Dis
More information化学療法
第 60 回 医 療 者 がん 研 修 会 2015/9/17 もっと 知 りたい 膀 胱 癌 治 療 尿 管 癌 膀 胱 癌 の 化 学 療 法 広 島 市 立 広 島 市 民 病 院 泌 尿 器 科 副 部 長 弓 狩 一 晃 泌 尿 器 科 での 化 学 療 法 経 尿 道 的 投 与 経 静 脈 動 脈 的 投 与 膀 胱 癌 治 療 1 表 在 癌 経 尿 道 的 膀 胱 腫 瘍 切 除
More information瀬田唐橋景観検討について
3 3 12,174 /12hr 1,110 /12hr 3,066 /12hr 172.0m 51.75m 23.5+5@25.0+23.5m 3@17.25m 14.0m 15.0m 5 6 2009 12 3 2010 2 25 6/22 8/24 10/18 11/16 1/13 1797 16 15 15 13 6 (S49) 54 7 23-2 24 54 50
More information経済論集 46‐1(よこ)(P)/2.三崎
1 1 14 2 1866 8 20 20 2 4 1871 20 3 4 2 1969 9 12 28 33 3 1970 35 5 1965 p.119. 1995 p.67 1960 p.86. 1965 p.120. 1927 p.5. 1942 p.127, p.129. 10 1877 7 12 16 6 10 7 10 1877 8 7 6 8 16 25 29 10 1877 9 1
More information07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More informationml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
More information日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
More informationAtlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More information437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
More informationcladribine 2-CdA ADA DCF HCL IFN- MTD LD50 LD90 DLT MDACC RWJPRI NHL ATL CLL 2-CdATP 5 -NT dckase (2-chloro-2 -deoxyadenosine) adenosine deaminase deoxycoformycin( ) hairy cell leukemia - (interferon alfa)
More informationEP7000取扱説明書
EP7000 S0109-3012 3 47 811 1213 1419 2021 53 54 5560 61 6263 66 2223 2427 2830 3133 3436 3740 4142 4344 45 46 4750 5152 2 4 5 6 7 1 3 4 5 6 7 8 9 15 16 17 18 13 EP7000 2 10 11 12 13 14 19 20 21 22 23 24
More information審査報告書(案)
19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET
More information13,825,228 3,707,995 26.8 4.9 25 3 8 9 1 50,000 0.29 1.59 70,000 0.29 1.74 12,500 0.39 1.69 12,500 0.55 10,000 20,000 0.13 1.58 30,000 0.00 1.26 5,000 0.13 1.58 25,000 40,000 0.13 1.58 50,000 0.00 1.26
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More informationPowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
More informationがん化学(放射線)療法レジメン申請書
申請期日 がん化学 ( 放射線 ) 療法レジメン申請書 記載不備がある場合は審査対象になりません * は記入不要です 受付番号 診療科名呼吸器外科がん腫 ( コード ) 診療科長名 申請医師名 審査区 ( 下記をチェックしてください ) レジメン登録ナンバー 登録申請日 登録確認日 通常審査を希望 登録削除日 迅速審査を希望 注 1) 注 1) 迅速審査は患者限定となります がん種レジメン名実施区使用類適応類
More informationNo
No. 1 2 No. 3 4 5 6 7 8 9 10 11 12 No. 13 14 15 16 17 18 19 20 21 22 23 24 25 26 No. 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 No. 44 45 46 47 48 49 50 51 52 No. 53 54 55 56 57 58 59 60 61 62
More information1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Journal Physiology, American Journal of Physiology, Journal of Physiology, Journal of Autonomic Nervous System, American Journal of Physiology,
More information200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
More information*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati
*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combination with angiotensin II induced hyperten sion chemotherapy
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More informationSynagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
More informationuntitled
1 2 3 http://www.info.pmda.go.jp/ 4 5 6 7 8 9 10 11 (Quincke s edema) 12 13 梗 疼 () 14 15 J Allergy Clin Immunol 115;S483-S523, 2005 16 17 IgE IgE IgE 18 19 20 21 腿 22 Hydrocortisone 100 200 mg 5 mg/kg
More information....
2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin
More information5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
More information無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
More information外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)
p,p -DDT p,p -DDE p,p -DDD trans- cis- trans- cis- (PBB) (BaP) 25ng/L 5µg/kg GC/MS-SIM GC/MS-SIM GC/MS-SIM GC/MS-SIM (2-, 3-, 4- ) (4,4'- ) p,p'-ddt- 13 C 12 HCB- 13 C 6 BaP-d 12 -d10 -d 10 p- -d 14 1000
More informationuntitled
i ii iii EC 1-1 1 (1) (2) 3,0005,000 3 1 Web 2 Web 1-1 3 (3) (4) 18111812 (5) (1) (2) Web 4 1-2 1 (3) (4) 1812191 (5) 5 1.1 Web 2-1 6 (1) 2-1 387 2-2 7 (2) Web 57% Web 28% 2-3 (3) 43% 56% 2 50%1 26% 2-2
More information5 Armitage x 1,, x n y i = 10x i + 3 y i = log x i {x i } {y i } 1.2 n i i x ij i j y ij, z ij i j 2 1 y = a x + b ( cm) x ij (i j )
5 Armitage. x,, x n y i = 0x i + 3 y i = log x i x i y i.2 n i i x ij i j y ij, z ij i j 2 y = a x + b 2 2. ( cm) x ij (i j ) (i) x, x 2 σ 2 x,, σ 2 x,2 σ x,, σ x,2 t t x * (ii) (i) m y ij = x ij /00 y
More information要望番号 ;Ⅱ-24 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中
未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者 ( 該当するものにチェックする ) 学会 ( 学会名 ; 特定非営利活動法人日本臨床腫瘍学会 ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 8 位 ( 全 33 要望中 ) 要望する医薬品 成 分 名 ( 一般名 ) 販 売 名 会 社 名 国内関連学会 amoxicillin-clabulanate
More informationPowerPoint Presentation
1 Cutaneous T- cell lymphoma) 2) 2001 WHO - - - PS LDH soluble IL- B 38.5 C 10 International Prognostic Index IPI International prognostic factor and index Prognostic factor >60 LDH > PS 2-4 Stage III
More information証券訴訟を巡る近時の諸問題—流通市場において不実開示を行った提出会社の責任を中心に—
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 1 17 4 1 16 2 3 4 WG 1 16 16 18 21 22 24 4 2 16 97 15 12 24 http://www.fsa.go.jp/singi/singi_kinyu/siryou/kinyu/dai1/f- 20031224_sir/02.pdf
More informationuntitled
( ) 200133 3 3 3 3, 7 347 57 10 i ii iii -1- -2- -3- -4- 90011001700mm -5- 4.2 1991 73.5 44.4 7.4 10.5 10.5 7.4 W 3 H 2.25 H 2.25 7.4 51.8 140.6 88.8 268.8m 5,037.9m 2 2mm 16cm916cm 10.5 W 3 H 2.25 62.8
More information